What are the indications and recommended dosing of thiamine (vitamin B1) for oncology patients at risk of deficiency or with suspected Wernicke’s encephalopathy?

Thiamine Use in Oncology

Oncology patients are at significant risk for thiamine deficiency and should receive prophylactic thiamine supplementation, with dosing ranging from 100-300 mg IV daily for hospitalized/at-risk patients, escalating to 500 mg IV three times daily for suspected or confirmed Wernicke's encephalopathy.

Risk Factors in Cancer Patients

Cancer patients face multiple overlapping risk factors for thiamine deficiency 1:

• Malnutrition and poor oral intake (common in advanced cancer)
• Increased metabolic demands from the malignancy itself
• Gastrointestinal dysfunction from tumor location or surgical resections
• Chemotherapy-induced nausea and vomiting
• Parenteral nutrition without adequate supplementation

Thiamine reserves deplete within 20 days of inadequate intake 1, making early intervention critical. A recent study found thiamine deficiency in 36% of end-of-life cancer patients admitted to palliative care, particularly those with serum albumin <3.0 g/dL 2.

Clinical Presentations to Recognize

Wernicke's Encephalopathy

The classic triad (confusion, ataxia, ophthalmoplegia) is often incomplete in cancer patients 3, 4, 5. Look for:

• Altered mental status or confusion
• Gait unsteadiness
• Visual disturbances or nystagmus
• Drowsiness or impaired consciousness

Critical pitfall: Do NOT administer IV dextrose before thiamine in at-risk patients—this can precipitate acute Wernicke's encephalopathy 6, 7, 8.

Other Manifestations

• Unexplained lactic acidosis 1
• Cardiovascular symptoms (wet beriberi)
• Peripheral neuropathy

Dosing Recommendations by Clinical Scenario

Prevention in At-Risk Hospitalized Cancer Patients

100-300 mg IV daily 1

• Use for patients with poor oral intake, active chemotherapy, or gastrointestinal symptoms
• Continue throughout hospitalization and transition to oral maintenance

Refeeding Syndrome Prevention

300 mg IV before initiating nutrition, then 200-300 mg IV daily for ≥3 days 1

• Essential for malnourished patients starting enteral or parenteral nutrition
• Add potassium, phosphate, and magnesium monitoring 9

Suspected or Confirmed Wernicke's Encephalopathy

500 mg IV three times daily 1, 4

• Continue for 3-5 days or until symptom resolution
• Then reduce to 250 mg IV daily for 3-5 days
• Case reports demonstrate rapid improvement (within 36 hours) with this high-dose regimen 4

Important: The traditional 100 mg daily dosing is inadequate for treating Wernicke's encephalopathy 8, 4, 10, 11. European guidelines explicitly recommend 500 mg three times daily for encephalopathy of uncertain etiology 1.

Maintenance After Deficiency Treatment

50-100 mg oral daily 1

• Continue indefinitely if risk factors persist
• Transition from IV once acute symptoms resolve and oral intake is adequate

Enteral/Parenteral Nutrition

• Enteral nutrition: 1.5-3 mg daily in standard formulations 1
• Parenteral nutrition: Minimum 2.5 mg daily 1; administer first dose of thiamine before starting PN in high-risk patients 12

Route Selection

Use IV route when:

• Acute neurological symptoms present
• Severe nausea/vomiting preventing oral intake
• Malabsorption suspected
• Refeeding risk exists
• Any acute illness with suspected inadequate recent intake 1

Oral route acceptable for:

• Mild deficiency in stable outpatients (10 mg daily × 1 week, then 3-5 mg daily × 6 weeks) 1
• Maintenance therapy after IV correction
• Chronic supplementation in stable patients

Monitoring

Measure thiamine levels in:

• Patients with encephalopathy of unclear etiology
• Those requiring prolonged medical nutrition
• Refeeding syndrome cases
• Unexplained lactic acidosis or cardiomyopathy 1

Test: RBC or whole blood thiamine diphosphate (ThDP) 1

However, do NOT delay treatment while awaiting laboratory results if clinical suspicion exists 1, 4. Empiric treatment is appropriate and safe.

Safety Profile

Thiamine has no established upper limit and is remarkably safe 1:

• Excess is excreted in urine
• Anaphylaxis is extremely rare with IV administration
• Doses >400 mg may cause mild nausea or ataxia

The risk of undertreating far exceeds any risk from high-dose supplementation in suspected deficiency.

Special Considerations

Cancer-specific factors:

• Head and neck cancer patients are particularly vulnerable due to dysphagia and treatment-related mucositis 5
• Gastrointestinal malignancies increase risk through malabsorption 1
• Terminal cancer patients with low albumin (<3.0 g/dL) warrant heightened vigilance 2

Drug interactions:

• Diuretic therapy increases renal losses—consider 50 mg oral daily prophylaxis 1
• Continuous renal replacement therapy: 100 mg daily 1

1, 6, 12, 1, 12, 9, 8, 3, 4, 10, 11, 2, 5